PILA PHARMA is a privately held clinical stage pharmaceutical company based in Malmö, Sweden.
PILA PHARMA is developing a novel type of oral anti-diabetic agent: a TRPV1 antagonist for the treatment of diabetes.
XEN-D0501, the recently purchased, safe clinical development candidate, will enter the first clinical trials in type-2 diabetic patients in 2017.

Pila_Logo_Orang-2x

PILA PHARMA yesterday won the title “Årets pitchare 2016” at the ALMI Invest Seed Day in Stockholm, Sweden!
The 1-min pitch competition was held amongst 17 selected out of ALMI Invests 400 portfolio companies.

(06-Dec-2016)
Nextbig 2016 3
Nextbig 2016 3
Nextbig 2016 2
Nextbig 2016 5
Nextbig 2016 4
Nextbig 2016 6

Investor presentation at ‘Next Big Thing’ (by Blasieholmen Investment Group)
Moderna Museet, Stockholm, Sweden

Watch the presentation here
Direct link to presentation here

(02-Dec-2016)
pila_modernamuseet
Interview
DorteX Gram

“Min uppfinning kom och hämtade tillbaka mig”
Dr. Dorte X. Gram, CEO of PILA Pharma was interviewed by Sydsvenskan, Sweden.

Read the article in swedish here

(04-Dec-2016)
01-omslag-nordic-life-science-nr-03-2016

We are proud to be on the cover of the September 2016 issue of Nordic Life Science Magazine as representatives of Nordic Life Science companies.

Read the article here
Read the magazine here

(08-Apr-2016)

At BioEurope Spring in Stockholm in April 2016 Dr. Dorte X. Gram, CEO of PILA Pharma was interviewed by the organizers about the current status and our plans going forward.

Please find the links below:
partnering360.com